About 30% of COVID patients develop "Long COVID," UCLA research finds
- Details
- Category: Research
New UCLA research finds that 30% of people treated for COVID-19 developed Post Acute Sequelae of COVID-19 (PASC), most commonly known as “Long COVID.” People with a history of hospitalization, diabetes, and higher body mass index were most likely to develop the condition, while those covered by Medicaid, as opposed to commercial health insurance, or had undergone an organ transplant were less likely to develop it.
COVID-19 vaccine protects kids and teens from severe illness
- Details
- Category: Research
Results of a new multicenter study published in the New England Journal of Medicine found that vaccination with a primary series of the Pfizer-BioNTech mRNA COVID-19 vaccine reduced the risk of COVID-19-associated hospitalizations in children ages 5-11 years by two-thirds during the Omicron period.
Tumors change their metabolism to spread more effectively
- Details
- Category: Research
Cancer cells can disrupt a metabolic pathway that breaks down fats and proteins to boost the levels of a byproduct called methylmalonic acid, thereby driving metastasis, according to research led by scientists at Weill Cornell Medicine. The findings open a new lead for understanding how tumors metastasize, or spread to other tissues, and hints at novel ways to block the spread of cancer by targeting the process.
Study tracks COVID-19 antibodies over time
- Details
- Category: Research
The antibodies generated by Pfizer's COVID-19 vaccine rise more slowly and decline more quickly than those generated by the Moderna vaccine, according to a new study from UVA Health. The study also finds that older recipients of the Pfizer vaccine generated fewer antibodies than did younger recipients - but this wasn't the case for Moderna, where age did not appear to be a factor.
New COVID-19 nasal spray outperforms current antibody treatments in mice
- Details
- Category: Research
A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human clinical trials to treat COVID-19.
Designed computationally and refined in the laboratory, the new protein therapies thwarted infection by interfering with the virus' ability to enter cells.
New approach for delivery of anti-HIV antibody therapy shows promise in phase I clinical trial
- Details
- Category: Research
Since the first reports of HIV infection in the early 1980s, multiple clinical trials have tested potential vaccines against the virus, but unfortunately, HIV has numerous defense mechanisms that prevent a person's immune system from mounting an effective response following HIV vaccination. An alternative anti-HIV strategy called Vectored ImmunoProphylaxis (VIP) designed by researchers at the
Fighting viruses is as easy as breathing
- Details
- Category: Research
The average person will take more than 600 million breaths over the course of their life. Every breath stretches the lungs’ tissues with each inhale and relaxes them with each exhale. The mere motions of breathing are known to influence vital functions of the lungs, including their development in babies, the production of air-exchange-enhancing fluid on their inner surfaces, and maintenance of healthy tissue structure.
More Pharma News ...
- Researchers look to licorice for promising cancer treatments
- Cancer repair mechanism could be potential drug target
- NIH begins clinical trial evaluating second COVID-19 booster shots in adults
- New nasal spray treats Delta variant infection in mice, indicating broad spectrum results
- Alpaca nanobodies potently neutralize SARS-CoV-2 variants
- Aspirin may reduce death In hospitalized COVID-19 patients
- Novel therapeutic strategy shows promise against pancreatic cancer